AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort

Thursday, May 15, 2008 General News J E 4
TUSTIN, Calif., May 14 AMDL, Inc.(Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen,Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceuticalcompany. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDLengages in the research, development, manufacture, and marketing ofdiagnostic, pharmaceutical, nutritional supplement, and cosmetic productscurrently in China. The Company today announced that JPI has donated variouspharmaceutical products valued at more than $70,000, to the China Red Cross(Chengdu Branch) to provide medical support to the victims of the recentearthquake located in Shichuan Province, which devastated portions of China.

"Not only did our JPI management make this significant donation valued atmore than $70,000, it initiated a special trip to Sichuan to ensure that thedrugs reached the proper destinations," said Gary Dreher, CEO of AMDL. "Theinitiative taken by JPI signals its awareness and enthusiasm for its socialresponsibility. We do not expect that this earthquake will have any negativeimpact on sales of JJB and or YYB products, in fact, certain products mayexperience a higher than normal sales growth rate due to the disaster."

About Jade Pharmaceutical: JPI has access to the fastest growingpharmaceutical and consumer market in the world: China. AMDL, through itssubsidiaries, Jade currently manufactures large volume injection fluids,tablets and other related products, holding licenses for 133 products. It alsomanufactures 107 generic, over the counter and supplemental pharmaceuticalproducts under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtainedat

Forward-Looking Statements

This news release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Such statements aresubject to certain risks and uncertainties, and actual circumstances, eventsor results may differ materially from those projected in such forward-lookingstatements. The Company cautions readers not to place undue reliance on anyforward-looking statements. The Company does not undertake, and specificallydisclaims any obligation, to update or revise such statements to reflect newcircumstances or unanticipated events as they occur.Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 VoiceMail: 714.505.4460



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Progen Resumes Phase 1 Development of Anti-Cancer ...
Ralphs Expands Discounted Generic Drug Program